Fig 1: OM-MSCs mitigate OGD/R-induced ROS overproduction and mitochondrial dysfunction through upregulation of UBIAD1. N2a cells were transfected with UBIAD1-specific siRNA (UBIAD1 RNAi) or a non-specific control siRNA. (A,B) The intracellular ROS levels were examined by DCFH-DA in N2a cells knocked down by UBIAD1. (C–E) The total SOD, GSH-PX, and MDA activities in N2a were assessed. (F–G) Determination of the mitochondrial membrane potential was carried out using the JC-1 probe. (H) The ATP content in N2a cells. (I) The cell viability was examined by CCk-8 assay. (J,K) The apoptotic N2a cells knocked down by UBIAD1. All data are displayed as mean ± SEM (n = 3). (*P < 0.05, **P < 0.01 vs. Con/control RNAi, #P < 0.05, ##P < 0.01 vs. OGD/R/control RNAi, &P < 0.05, &&P < 0.01 vs. OGD/R + MSCs/control RNAi, ns. no significance).
Fig 2: Expression of UBIAD1 upregulated by OM-MSC treatment. (A,B) The protein expression of UBIAD1 in the peri-infarct cortex was detected using Western blotting. Data are displayed as mean ± SEM (n = 3). (*P < 0.05, **P < 0.01 vs. sham-operated, #P < 0.05, ##P < 0.01 vs. MCAO + saline.) (C,D) The protein expression of UBIAD1 in the N2a cells was detected using Western blotting. (E) The mRNA expression of UBIAD1 in the N2a cells was detected by qPCR. Data are displayed as mean ± SEM (n = 3). (*P < 0.05, **P < 0.01 vs. control, #P < 0.05, ##P < 0.01 vs. OGD/R.) (F–H) Representative expression of UBIAD1 after transfection with siRNA. Data are displayed as mean ± SEM (n = 3). (**P < 0.01 vs. Con/control RNAi, #P < 0.05, ##P < 0.01 vs. OGD/R/control RNAi, &&P < 0.01 vs. OGD/R + MSCs/control RNAi).
Supplier Page from Abcam for Anti-UBIAD1 antibody - C-terminal